dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Oaknin Benzaquen, Ana Mazaltob |
dc.contributor.author | Oza, Amit M. |
dc.contributor.author | Lorusso, Domenica |
dc.contributor.author | Dean, Andrew |
dc.contributor.author | Colombo, Nicoletta |
dc.contributor.author | Aghajanian, Carol |
dc.date.accessioned | 2022-03-14T12:23:21Z |
dc.date.available | 2022-03-14T12:23:21Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Oaknin A, Oza AM, Lorusso D, Aghajanian C, Dean A, Colombo N, et al. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. Cancer Med. 2021 Oct;10(20):7162–73. |
dc.identifier.issn | 2045-7634 |
dc.identifier.uri | https://hdl.handle.net/11351/7156 |
dc.description | Assaigs clínics; Oncologia ginecològica; Càncer de les dones |
dc.description.sponsorship | A.O. has served on advisory boards for Clovis Oncology, AstraZeneca, Deciphera, Genmab/Seattle Genetics, GlaxoSmithKline/Tesaro, ImmunoGen, Merck/Merck Sharp & Dohme, Mersana Therapeutics, PharmaMar, and Roche; has received support for travel or accommodation from Clovis Oncology, AstraZeneca, PharmaMar, and Roche; and reports institutional research grant support from Clovis Oncology, AbbVie Deutschland, Ability Pharmaceuticals, Advaxis, Aeterna Zentaris, Amgen, Aprea Therapeutics, Eisai, ImmunoGen, Merck/Merck Sharp & Dohme, Millennium Pharmaceuticals, PharmaMar, Roche, and Tesaro. |
dc.language.iso | eng |
dc.publisher | Wiley |
dc.relation.ispartofseries | Cancer Medicine;10(20) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject | Ovaris - Càncer - Tractament |
dc.subject.mesh | Ovarian Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Treatment Outcome |
dc.title | Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1002/cam4.4260 |
dc.subject.decs | neoplasias ováricas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | resultado del tratamiento |
dc.relation.publishversion | https://doi.org/10.1002/cam4.4260 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Oaknin A] Gynaecologic Cancer Programme, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Oza AM] Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. [Lorusso D] Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies and Gynecologic Oncology Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy. [Aghajanian C] Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA. [Dean A] Oncology, St John of God Subiaco Hospital, Subiaco, Western Australia, Australia. [Colombo N] Gynecologic Cancer Program, University of Milan-Bicocca and European Institute of Oncology IRCCS, Milan, Italy |
dc.identifier.pmid | 34549539 |
dc.identifier.wos | 000697615600001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |